Immunotherapy: Bad B cells

Nature Reviews Cancer 18, 66 (2018). doi:10.1038/nrc.2018.7 Author: Anna Dart Combination immune checkpoint blockade with anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and anti-programmed cell death protein 1 (PD1) leads to higher response rates in patients with melanoma than either single agent alone. Yet, a drawback of this combination is an increase in immune-related adverse events.
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Tags: Research Highlight Source Type: research